Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research investigates the impact of combining respiratory multiplex PCR mPCR with algorithm-based therapy, designed using local epidemiology, on improving early optimization of initial antibiotic treatment in critically ill patients with ventilator-associated pneumonia VAP. The study compares this combined strategy to a conventional antibiotic treatment approach guided by clinician discretion and best practice recommendations. It is a bicentric, parallel-group, randomized controlled trial focused on early antibiotic optimization within 24 hours after respiratory sampling. Participants diagnosed with VAP undergo deep respiratory sample collection through mini bronchoalveolar lavage BAL, either via bronchoscopy or blind mini BAL. In the intervention group, samples are analyzed with both conventional methods and a broad-panel respiratory mPCR within 12 hours. Results from mPCR guide clinicians in adjusting antibiotic therapy early using a specific algorithm. The control group receives antibiotic therapy adjustments based on conventional sample analysis and clinical judgment without mPCR or algorithm support. During the study, researchers monitor the timing and effectiveness of antibiotic optimization, duration of broad-spectrum antibiotic exposure, clinical cure rates, mechanical ventilation use, ICU stay length, organ failure-free days, mortality, and infection rates. Laboratory tests include conventional cultures and susceptibility testing, with mPCR performance evaluated against these standards. The study also assesses hospital admission costs. Participation continues through treatment and outcome assessments up to 28 days, with safety and efficacy measures tracked throughout.
Actively Recruiting
This observational study aims to assess the feasibility of estimating how common stage 4 and 5 chronic kidney disease CKD is in the Gard department of France. Researchers will compare data from laboratory databases with records of patients seen by nephrologists to understand if laboratory-verified care needs match actual nephrology care delivery as recommended by the French High Authority of Health HAS. The study does not involve any treatments or interventions but focuses on analyzing existing laboratory data and nephrology patient records over a 12-month period. The primary goal is to measure the prevalence of advanced CKD in the region and evaluate how well patients with CKD are identified and managed by nephrologists. Participants with stage 4 or higher CKD will be observed through data collected from laboratories and nephrologists. Researchers will measure the number and proportion of patients with advanced CKD, assess reporting accuracy by nephrologists, and identify patients not seen by nephrologists. The study will last until December 2027, with ongoing data collection and analysis for up to 12 months.